Yemaachi and Institut Pasteur Tunis Forge Oncogenetics Partnership to Sequence and Characterise Inflammatory Breast Cancer in Patients of African Descent
Partnership is emblematic of a global effort to characterise cancer development and progression in individuals of African descent, who have traditionally been excluded from genomic oncology studies and clinical trials 22nd October 2024, Tunis, Tunisia — Precision oncology company Yemaachi Biotech and Institut Pasteur Tunis today announced a research partnership investigating genomics in inflammatory breast […]
Oxford Nanopore announces participation in the PROGRESS study, with Yemaachi Biotech
A consortium of Yemaachi Biotech, Pediatric Oncology Units at Korle Bu Teaching Hospital, Komfo Anokye Teaching Hospital and Greater Accra Regional Hospital, and Newcastle University, have come together with Oxford Nanopore to support improved outcomes for childhood leukaemias in Ghana.
Team SAMBAI, including Yemaachi Biotech, named as recipient of prestigious Cancer Grand Challenges award
Team SAMBAI, led by Melissa B. Davis, PhD, of Morehouse School of Medicine, and comprised of collaborators from 14 institutions globally will receive $25M from Cancer Grand Challenges over five years to take on the challenge of cancer inequities
Yemaachi Furthers African Cancer Research Agenda With New Breast Cancer Mutation, Research Networks
Yemaachi Biotech is preparing to expand a whole-exome sequencing pilot study, while pushing forward several other pan-African cancer research initiatives.
Yemaachi Presents Findings on Mutation Profiles of Ghanaian Women with Breast Cancer at AORTIC 2023; Announces Formation of African Clinical Cancer Research Network
Results presented in collaboration with Paemka Research Group at the University of Ghana represent largest sequencing study of its kind conducted entirely in Africa to date; Company’s cancer network will advance and scale precision oncology research and collaborations across the continent
Global team to study international differences in COVID-19 immunity
Supported by £3.1 million from the Wellcome Trust, the newly-created WWW Consortium links three leading studies in West Africa (Yemaachi Biotech Heritage Study), the West Indies (Windfall Study in Kingston, Jamaica), and West London (the Legacy Study), each tracking how both the virus and our immunity has evolved against COVID-19.
Ghana startup strives for greater African representation in cancer research
As one of Ghana’s only labs equipped for molecular analysis, Bediako’s team have tasked themselves with collecting data they believe will advance the development of medicine for cancer patients throughout the continent and diaspora
Yemaachi, Africa’s Cancer Research Company, Raises Seed Round To Diversify Genomic Datasets & Advance Precision Oncology Globally
Yemaachi Biotech announced today the close of a $3 million seed round to advance its mission of diversifying precision oncology globally. V8 Capital led the round, with LifeLine Family Heritage Fund, Y Combinator, Tencent, LoftyInc Capital, VestedWorld, V Square Capital and Ethan Perlstein also participating.
Yemaachi Launches HPV Molecular Test in Ghana for At-Home Cervical Cancer Risk Assessment
GenomeWeb covers Yemaachi’s launch of its Sheba HPV Test, a convenient discreet way for women to screen themselves for HPV and assess their risk for cervical cancer.